Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Synthetic Conjugated estrogens, B · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Synthetic Conjugated estrogens, B | DRUG | 1 (0.3mg) tablet daily |
| Placebo | OTHER | 1 tablet daily |
Inclusion Criteria: * Naturally or surgically postmenopausal * Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse) Exclusion Criteria: * Known sensitivity or contraindication to estrogens or progestins * History or current diagnosis of endometria...
Synthetic Conjugated estrogens, B is used for the treatment of vulvovaginal atrophy in menopausal women. It is a small molecule being developed by Teva Pharmaceutical Industries Limited for the endocrine condition of menopause. The drug is currently in Phase 3 clinical development.
Synthetic Conjugated estrogens, B is a synthetic conjugated estrogen. It works by replacing or supplementing estrogen hormones in the body to treat symptoms associated with menopause, such as vulvovaginal atrophy. The drug is designed to provide estrogenic effects to alleviate these menopausal symptoms.
Synthetic Conjugated estrogens, B is being developed by Teva Pharmaceutical Industries Limited, a company traded under the ticker TEVA. The drug is currently in Phase 3 clinical trials for the treatment of vulvovaginal atrophy in menopausal women.
Synthetic Conjugated estrogens, B is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 3 trial has been completed to evaluate its safety and efficacy for treating vulvovaginal atrophy in menopausal women.
Synthetic Conjugated estrogens, B has one completed Phase 3 clinical trial, identified as NCT00196378. This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of Enjuvia 0.3 mg for vulvovaginal atrophy in 300 menopausal women in the United States.
Yes, Synthetic Conjugated estrogens, B is also known as Enjuvia. The Phase 3 clinical trial NCT00196378 evaluated Enjuvia 0.3 mg for the treatment of vulvovaginal atrophy, confirming that Enjuvia is the brand name for this synthetic conjugated estrogen product.